Czech National Bank Purchases 26,353 Shares of Bristol-Myers Squibb (NYSE:BMY)

Czech National Bank grew its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 6.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 466,102 shares of the biopharmaceutical company's stock after purchasing an additional 26,353 shares during the period. Czech National Bank's holdings in Bristol-Myers Squibb were worth $28,428,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Pinney & Scofield Inc. acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $25,000. Park Square Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $26,000. Fairway Wealth LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Transce3nd LLC acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Finally, Global Wealth Strategies & Associates increased its holdings in shares of Bristol-Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Trading Up 0.2%

Shares of BMY stock traded up $0.08 on Thursday, reaching $48.03. 5,174,171 shares of the stock were exchanged, compared to its average volume of 13,334,227. The stock has a market cap of $97.74 billion, a PE ratio of -10.87, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock has a 50 day moving average price of $49.82 and a 200 day moving average price of $55.19.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the company posted ($4.40) earnings per share. The firm's quarterly revenue was down 5.6% on a year-over-year basis. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BMY shares. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Jefferies Financial Group decreased their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.